Showing 5381-5390 of 5643 results for "".
- 2018 Best of Eyetubehttps://modernod.com/news/2018-best-of-eyetube/2476238/Cataract & Refractive Surgery Today (CRST) has compiled the best content of 2018 from Eyetube.net, the leading video resource for ophthalmologists. Below are descriptions of a few of the top videos. To view all of the videos and their descriptions, click
- AMD Monitoring Comes Home: The Promise of Innovative Remote Techhttps://modernod.com/news/amd-monitoring-comes-home-the-promise-of-innovative-remote-tech/2476239/Age-related macular degeneration (AMD) is the leading cause of severe vision loss in older Americans. AMD is a degenerative disease that affects the macula, or the central part of the retina, which has the highest density of photoreceptors, allowing for high-resolution central visual acuity. An e
- Carl Zeiss Meditec Completes Acquisition of IanTECHhttps://modernod.com/news/carl-zeiss-meditec-completes-acquisition-of-iantech/2476242/Carl Zeiss Meditec has officially completed its acquisition of IanTECH, a privately held company focused on technology solutions for micro-interventional cataract surgery headquartered in Reno, Nevada. IanTECH is the maker of the miLOOP Lens Fragmentation Device, which is the first in a li
- iSTAR Medical’s MINIject Maintains Exceptional Results in First-in-Human Trial One Year Post-Surgery (STAR-I)https://modernod.com/news/istar-medicals-miniject-maintains-exceptional-results-in-first-in-human-trial-one-year-post-surgery-star-i/2476244/iSTAR Medical announced 1-year results of the first-in-human, microinvasive glaucoma surgery (MIGS) STAR-I trial, for the MINIject device in a standalone setting. Results demonstrate that MINIject is safe and highly effective in achieving significant IOP reduction, as well as easing medication bu
- Alcon Acquires Tear Film Innovationshttps://modernod.com/news/alcon-announces-acquisition-of-tear-film-innovations/2476248/Alcon announced that it has acquired Tear Film Innovations, maker of the iLux device to treat meibomian gland dysfunction. Financial terms of the deal were not disclosed. Handheld and portable, the iLux enables eye care professionals to directly target a patient’s blocked meibomian
- First IC-8 Small Aperture IOL Implanted in the United Stateshttps://modernod.com/news/first-ic-8-small-aperture-iol-implanted-in-the-united-states/2476252/AcuFocus announced that the first US patient has been implanted with the IC-8 small aperture IOL as part of its pivotal study of the IC-8 lens in cataract patients. The company recently announced approval for an investigational device exemption (IDE) from the FDA to conduct the study. The
- EyePoint Pharmaceuticals Added to NASDAQhttps://modernod.com/news/eyepoint-pharmaceuticals-added-to-nasdaq/2479607/EyePoint Pharmaceuticals announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI). EyePoint’s addition to the NBI will become effective prior to market open on Monday, December 24, 2018. The NASDAQ Biotechnology Index is designed to track the perform
- ProQR Announces Publication of QR-110 Data for Leber’s Congenital Amaurosis 10https://modernod.com/news/proqr-announces-publication-of-qr-110-data-for-lebers-congenital-amaurosis-10/2479608/ProQR Therapeutics announced the publication of a peer-reviewed manuscript describing the previously announced interim results of a clinical trial of QR-110 for the treatment of Leber’s congenital amaurosis 10 (LCA10) in the journal
- Innovent Announces Two Clinical Studies with the Anti-VEGF Monoclonal Antibody IBI305, a Potential Avastin Biosimilarhttps://modernod.com/news/innovent-announces-two-clinical-studies-with-the-anti-vegf-monoclonal-antibody-ibi305-a-potential-avastin-biosimilar/2479615/Innovent Biologics announced that IBI305, a recombinant humanized anti-VEGF monoclonal antibody being developed as a potential biosimilar to Avastin (bevacizumab), has met predefined primary endpoints in two randomized, head to head, clinical trials comparing IBI30
- The Number of Optometric Practices Offering neurolens Contoured Prism Lenses More Than Quadrupled in 2018https://modernod.com/news/the-number-of-optometric-practices-offering-neurolens-contoured-prism-lenses-more-than-quadrupled-in-2018/2479617/Costa Mesa, California-based neurolens announced that adoption of their prescription lenses has grown among US optometric (OD) practices and by year end, 31 states will carry the company’s neurolenses and the neurolens measurement device. neurolenses are the first and only prescripti